Jeffrey currently focuses on development of specific serine protease inhibitors based on Sunflower Trypsin Inhibitor 1 scaffold – application for skin conditions with aberrant serine protease activities. Jeffrey is developing and synthesising a novel inhibitor predominantly only for kallikrein 5 (KLK5), a protease involving in the pathogenesis of atopic dermatitis (AD, eczema) and Netherton syndrome (NS) ; and ii) examine the potential of SFTI inhibitory effect for the type II transmembrane serine protease (TMPRSS2), a serine protease involved in the priming of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike proteins (S-protein), to see whether we can use SFTI as a scaffold to develop an inhibitor for TMPRSS2, which it could provide a new way to prevent/reduce the risk of virus infection for patients with chronic inflammatory skin condition such as AD and NS.